Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.69 |
| ▸ | LPL | P06858 | 12/20 | 0.69 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661288 | 0.94 | LPL (0.59) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL2707320 | 0.89 | LIPG (0.83) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL24608995 | 0.89 | LIPG (0.83) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL30963065 | 0.88 | LIPG (0.64) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL28389622 | 0.83 | LIPG (0.88) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL12681706 | 0.83 | LIPG (0.74) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL17423566 | 0.83 | CA1 (0.53) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL23812599 | 0.83 | LPL (0.50) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL23277196 | 0.83 | LIPG (0.57) | LIPGLPL | |
| SCHEMBL228212 | 0.82 | LPL (0.71) | LIPGLPLCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255151-A2 | SPIRO[FLUORENE-9,9'-(THIO)XANTHENE] COMPOUNDS | Merck Patent GmbH (DE) | 2023-10-04 | — | — | EP | disclosed |
| EP-4113643-B1 | SPIRO[FLUORENE-9,9'-(THIO)XANTHENE] COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-08-09 | — | — | EP | disclosed |
| EP-4113643-B1 | SPIRO[FLUORENE-9,9'-(THIO)XANTHENE] COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-08-09 | — | — | EP | disclosed |
| EP-3523834-B1 | ELECTRONIC DEVICE | MERCK PATENT GMBH (DE) | 2023-01-25 | — | — | EP | disclosed |
| EP-4113643-A1 | ELECTRONIC DEVICE | Merck Patent GmbH (DE) | 2023-01-04 | — | — | EP | disclosed |
| US-11538996-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2022-12-27 | — | — | US | disclosed |
| US-20220213022-A1 | COMPOUNDS, LIQUID COMPOSITIONS INCLUDING COMPOUNDS, AND ELECTROLUMINESCENT DEVICES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-07-07 | — | — | US | disclosed |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| EP-3983392-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX Cardio, LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206843-A | Compounds for modulating proprotein convertase subtilisin/Kexin type 9(PCSK9) | SRX心脏有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20140357898-A1 | NOVEL POLYMERS | BASF SE (DE) | 2014-12-04 | — | — | US | disclosed |
| US-8841411-B2 | Polymers | BASF SE (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8841411-B2 | Polymers | BASF SE (DE) | 2014-09-23 | — | — | US | disclosed |
| US-20110152491-A1 | NOVEL POLYMERS | BASF SE (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| US-20090048413-A1 | Method for Production of Conjugated Polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-02-19 | — | — | US | disclosed |
| EP-1997844-A1 | METHOD FOR PRODUCTION OF CONJUGATED POLYMER | Sumitomo Chemical Company, Limited (JP) | 2008-12-03 | — | — | EP | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152491-A1 | NOVEL POLYMERS | PLEC, PUF60, VIM | LIPG 980/4885LPL 483/4885CA1 4415/4885 |
| US-20140357898-A1 | NOVEL POLYMERS | PLEC, PUF60, VIM | LIPG 980/4885LPL 483/4885CA1 4415/4885 |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | LIPG 9/4885LPL 6/4885CA1 4552/4885 |
| US-11538996-B2 | Materials for organic electroluminescent devices | RIF1, INTS9, LEF1 | LIPG 3521/4885LPL 3484/4885CA1 1587/4885 |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | LIPG 1517/4885LPL 3371/4885CA1 4787/4885 |
| US-20220213022-A1 | COMPOUNDS, LIQUID COMPOSITIONS INCLUDING COMPOUNDS, AND ELECTROLUMINESCENT DEVICES | ETV6, ELANE, XPOT | LIPG 2264/4885LPL 3060/4885CA1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.